| Disease Domain | Count |
|---|---|
| Neoplasms | 3 |
| Infectious Diseases | 3 |
| Endocrinology and Metabolic Disease | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 10 |
Target |
Mechanism 5-LOX inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism α-glucosidase inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jul 2025 |
Sponsor / Collaborator |
Start Date20 May 2024 |
Sponsor / Collaborator |
Start Date02 Feb 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Nitroimidazole‐Quinoline Derivatives(Guru Nanak Dev University) | Protozoan Infections More | Preclinical |
Compound 5d(Guru Nanak Dev University) ( aromatase ) | Estrogen receptor positive breast cancer More | Preclinical |
Analogues of arachidonic acid 1a ( 5-LOX x COX-2 ) | Inflammation More | Preclinical |
Compound 5e(Guru Nanak Dev University) ( aromatase ) | Estrogen receptor positive breast cancer More | Preclinical |
AD-64 | Metabolic Dysfunction Associated Steatohepatitis More | Preclinical |





